{"title": "Tratamiento antiinflamatorio en el s\u00edndrome de Stevens-Johnson y la necr\u00f3lisis epid\u00e9rmica t\u00f3xica: revisi\u00f3n sistem\u00e1tica de la literatura cient\u00edfica", "author": "Diana Carrillo; Luz Z\u00e1rate; Ana Ram\u00edrez; Carlos Serrano", "url": null, "hostname": null, "description": "Background: There is no specific treatment approved for toxic epidermal necrolysis and Stevens Johnson syndrome. Patients must be treated mainly by eliminating the triggering factor and general support. Our aim was to perform a systematic review to evaluate the effect of anti-inflammatory treatment in adults with Stevens Johnson syndrome or toxic epidermal necrolysis.Methods: Systematic, objective, exhaustive and reproducible search of original research was conducted in electronic databases (Cochrane Skin Group Specialized Register, the Cochrane Controlled Trials and CDSR, Trip database, MEDLINE, EMBASE, CINAHL, Biomed, NCBI, HINARI and LILACS using \u201cStevensJohnson Syndrome / drug therapy\u201d or \u201cStevens-Johnson Syndrome / therapy\u201d or \u201cToxic epidermal necrolysis / drug therapy\u201d or \u201cToxic epidermal necrolysis / therapy\u201d as key words with restriction to open trials and phase III clinical trials from 1998 to December 30, 2011 in Spanish or English languages. Grey literature was not included. Title or abstract were reviewed to identify clinical trials.Results: Only one randomized, double-blind, placebo-controlled study with thalidomide was identified, and 7 open clinical trials without a control group or historical control were included. The drug therapy used was immunoglobulin in four studies, cyclosporine in two, and methylprednisolone in one. Although the extensive skin detachment of more than 50%, mortality was 0% in two studies with cyclosporine, one death in the methylprednisolone group and one death in the immunoglobulin group. Mortality in the thalidomide group was 83%. In one study with high-dose of immunoglobulin, the observed mortality was 32% vs. 21% of predicted mortality and in the low-dose of immunoglobulin, predicted mortality was 32% compared to 10% of observed mortality.Conclusion: There seems to be some benefit from therapy with methylprednisolone, immunoglobulin and cyclosporine but randomized controlled clinical trials are needed to determine the efficacy of these therapies available. Thalidomide increased mortality in toxic epidermal necrolysis.", "sitename": "Revista de la Asociaci\u00f3n Colombiana de Dermatolog\u00eda y Cirug\u00eda Dermatol\u00f3gica", "date": "2012-10-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Tratamiento antiinflamatorio en el s\u00edndrome de Stevens-Johnson y la necr\u00f3lisis epid\u00e9rmica t\u00f3xica: revisi\u00f3n sistem\u00e1tica de la literatura cient\u00edfica\nResumen\nAntecedentes. No existe un tratamiento espec\u00edfico para el manejo de la necr\u00f3lisis epid\u00e9rmica t\u00f3xica y el s\u00edndrome de Stevens-Johnson. Los pacientes son tratados, principalmente, mediante la eliminaci\u00f3n del factor desencadenante y medidas de soporte. Nuestro objetivo fue hacer una revisi\u00f3n sistem\u00e1tica para evaluar el efecto del tratamiento antiinflamatorio en adultos con s\u00edndrome de Stevens-Johnson o necr\u00f3lisis epid\u00e9rmica t\u00f3xica.\nM\u00e9todos. Se hizo una b\u00fasqueda sistem\u00e1tica, objetiva y reproducible de estudios originales en bases de datos electr\u00f3nicas como Cochrane Skin Group Specialized Register, Cochrane Controlled Trials and CDSR, Trip database, MEDLINE, EMBASE, CINAHL, Biomed, NCBI, HINARI y LILACS. Se usaron los t\u00e9rminos clave \u201cStevens-Johnson syndrome / drug therapy\u201d o \u201cStevens-Johnson syndrome / therapy\u201d o \u201cToxic epidermal necrolysis / drug therapy\u201d o \u201cToxic epidermal necrolysis / herapy\u201d, con restricci\u00f3n a ensayos abiertos y estudios cl\u00ednicos de fase III desde 1998 hasta el 30 de diciembre de 2011, y a idioma espa\u00f1ol e ingl\u00e9s. No se incluy\u00f3 literatura gris y se revisaron t\u00edtulos y res\u00famenes para identificar los ensayos cl\u00ednicos.\nResultados. Se encontr\u00f3 un solo un ensayo cl\u00ednico controlado con uso de talidomida y siete ensayos abiertos sin grupo control o con un control hist\u00f3rico. Los f\u00e1rmacos usados fueron inmuglobulina en cuatro estudios, ciclosporina en dos y metilprednisolona en uno. A pesar del extenso compromiso de la piel, de m\u00e1s del 50 %, la mortalidad fue de 0 % en los dos estudios con ciclosporina, y hubo una muerte en el grupo con metilprednisolona y una en el grupo de inmunoglobulina. La mortalidad en el grupo con talidomida fue de 83 %. En un estudio con dosis altas de inmunoglobulina, la mortalidad observada fue de 32 % Vs. 21 % de la mortalidad predicha y, en el estudio con bajas dosis de inmunoglobulina, la mortalidad predicha fue de 32 % comparada con la mortalidad observada del 10 %.\nConclusi\u00f3n. Parece existir alg\u00fan beneficio en el tratamiento con metilprednisolona, inmunoglobulina y ciclosporina, pero se requieren ensayos cl\u00ednicos controlados para determinar la eficacia de estos f\u00e1rmacos. La talidomida aument\u00f3 la mortalidad en los pacientes con necr\u00f3lisis epid\u00e9rmica t\u00f3xica.\nReferencias bibliogr\u00e1ficas\n2. Crosi A, Borges GS, Est\u00e9vez CF. Reacciones adversas medicamentosas graves: s\u00edndrome de Stevens-Johnson y necr\u00f3lisis epid\u00e9rmica t\u00f3xica. Rev Med Uruguay. 2004;20:172-7.\n3. Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review. Crit Care Med. 2011;39:1521-32\n4. Mesa T. S\u00edndrome de Stevens Johnson posterior al uso de carbamazepina en paciente esquizofr\u00e9nico. Reporte de caso. Psiquiatriacom. 2011;15: 1-16.\n5. Chen P, Lin J-J, Lu C-S, Ong C-T, Hsieh PF, Yang C-C, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126-33.\n6. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau J. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis . 1995;14:558-9.\n7. Mulvey J, Padowitz A, Lindley-Jones M, Nickels R. Mycoplasma pneumoniae associated with Stevens Johnson syndrome. Anaesth Intensive Care. 2007;35:414-7.\n8. Schalock PC, Dinulos JGH. Mycoplasma pneumoniae\u2013induced Stevens-Johnson syndrome without skin lesions: Fact or fiction? J Am Acad Dermatol. 2005;52:312-5.\n9. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau J-C, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: Results of an international prospective study. Arch Dermatol. 2002;138:1019-24.\n10. Tartarone A, Lerose R. Stevens-Johnson syndrome and toxic epidermal necrolysis: What do we know? Ther Drug Monit. 2010;32:669-72.\n11. Roujeau J-C, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-8.\n12. La Grenade L, Lee L, Weaver J, Bonnel R, Karwoski C, Governale L, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Safety. 2005;28:917-24.\n13. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau J-C, Revuz J, Wolkenstein P. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115 (2):149-53.14.\n14. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau J-C, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2005;126:272-6.\n15. Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev. 2002;4:CD991435.\n16. Shortt R, G\u00f3mez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246-55.\n17. Bachot N, Revuz J, Roujeau J-C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33-6.\n18. Tripathi A, Ditto AM, Grammer LC, Greenberger PA, McGrath KG, Zeiss CR, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: A total series of 67 cases. Allergy Asthma Proc. 2000;21:101-5.\n19. Wolkenstein P, Latarjet J, Roujeau J-C, Duguet C, Boudeau S, Vaillant L, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586-9.\n20. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol. 2003;83:430-2.\n21. Paquet P, Jacob E, Damas P, Pirson J, Pi\u00e9rard G. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res. 2005;297:266-73.\n22. Ar\u00e9valo J, Llorente JA, Gonz\u00e1lez-Herrada C, Jim\u00e9nez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473-8.\n23. Al-Mutairi N, Arun J, Osama N-E, Amr Z, Mazen A-S, Ibtesam E-A, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol. 2004;43:847-51.\n24. Araki Y, Sotozono C, Inatomi T, Ueta M, Yokoi N, Ueda E, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol . 2009;147:1004-11.\n25. Eisen E, Fish J, Shear N. Management of drug-induced toxic epidermal necrolysis. Cutan Med Surg. 2000;4:96-102.\n26. Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maitre B, Revuz J, et al. Open trial of ciclosporin treatment for StevensJohnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163:487-53.\n27. Friedman LM, Furberg CD, DeMets DL: Basic study design. In: Fundamentals of Clinical Trials, 4th Ed., edited by Friedman LM, Furberg CD, DeMets DL, New York, Springer, 2010, pp 68\u201371", "language": null, "image": null, "pagetype": null, "links": ["#pkp_content_main", "#pkp_content_nav", "#pkp_content_footer", "http://asocolderma.org.co/publicidad/www/delivery/ck.php?n=a938f22f&cb=INSERT_RANDOM_NUMBER_HERE", "http://asocolderma.org.co/publicidad/www/delivery/ck.php?n=a80e3f18&cb=INSERT_RANDOM_NUMBER_HERE", "                                                            https://revista.asocolderma.org.co/index.php/index\n                                                    ", "https://revista.asocolderma.org.co/index.php/asocolderma", "https://revista.asocolderma.org.co/index.php/asocolderma/issue/current", "https://revista.asocolderma.org.co/index.php/asocolderma/issue/archive", "https://revista.asocolderma.org.co/index.php/asocolderma/announcement", "https://revista.asocolderma.org.co/index.php/asocolderma/about", "https://revista.asocolderma.org.co/index.php/asocolderma/about", "https://revista.asocolderma.org.co/index.php/asocolderma/about/submissions", "https://revista.asocolderma.org.co/index.php/asocolderma/about/editorialTeam", "https://revista.asocolderma.org.co/index.php/asocolderma/about/contact", "https://revista.asocolderma.org.co/index.php/asocolderma/about/submissions", "https://revista.asocolderma.org.co/index.php/asocolderma/search/search", "#", "https://revista.asocolderma.org.co/index.php/asocolderma/user/setLocale/es_ES?source={$smarty.server.REQUEST_URI}", "https://revista.asocolderma.org.co/index.php/asocolderma/user/setLocale/en_US?source={$smarty.server.REQUEST_URI}", "https://revista.asocolderma.org.co/index.php/asocolderma/user/register", "https://revista.asocolderma.org.co/index.php/asocolderma/login", "https://revista.asocolderma.org.co/index.php/asocolderma/index", "https://revista.asocolderma.org.co/index.php/asocolderma/issue/archive", "https://revista.asocolderma.org.co/index.php/asocolderma/issue/view/22", "https://doi.org/10.29176/2590843X.246", "#resumen", "#author", "#references", "#citation", "#downloads", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/acm-sig-proceedings?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/acs-nano?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/apa?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/associacao-brasileira-de-normas-tecnicas?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/chicago-author-date?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/harvard-cite-them-right?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/ieee?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/modern-language-association?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/turabian-fullnote-bibliography?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/vancouver?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/download/ris?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/download/bibtex?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/article/view/246/224", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/acm-sig-proceedings?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/acs-nano?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/apa?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/associacao-brasileira-de-normas-tecnicas?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/chicago-author-date?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/harvard-cite-them-right?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/ieee?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/modern-language-association?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/turabian-fullnote-bibliography?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/get/vancouver?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/download/ris?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/citationstylelanguage/download/bibtex?submissionId=246&publicationId=219", "https://revista.asocolderma.org.co/index.php/asocolderma/issue/view/22", "http://asocolderma.org.co/publicidad/www/delivery/ck.php?n=aa3e8b59&cb=INSERT_RANDOM_NUMBER_HERE", "https://revista.asocolderma.org.co/index.php/asocolderma/user/setLocale/es_ES?source=%2Findex.php%2Fasocolderma%2Farticle%2Fview%2F246", "https://revista.asocolderma.org.co/index.php/asocolderma/user/setLocale/en_US?source=%2Findex.php%2Fasocolderma%2Farticle%2Fview%2F246", "https://revista.asocolderma.org.co/index.php/asocolderma/information/readers", "https://revista.asocolderma.org.co/index.php/asocolderma/information/authors", "https://revista.asocolderma.org.co/index.php/asocolderma/information/librarians", "http://revista.asocolderma.org.co/index.php/asocolderma/submission/wizard", "http://revista.asocolderma.org.co/index.php/asocolderma/about/submissions", "http://revista.asocolderma.org.co/index.php/asocolderma/et", "http://revista.asocolderma.org.co/index.php/asocolderma/about/editorialTeam", "https://scienti.minciencias.gov.co/publindex/#/revistasPublindex/detalle?tipo=R&idRevista=303", "https://latindex.org/latindex/ficha/14650", "https://portal.issn.org/resource/ISSN/2590-843X", "https://search.crossref.org/?q=https%3A%2F%2Fwww.researchgate.net%2Fjournal%2FRevista-de-la-Asociacion-Colombiana-de-Dermatologia-y-Cirugia-Dermatologica-1657-0448&from_ui=yes", "https://xjournals.com/collections/journals/TableofContent?qt=J1MNyTDRlWtsn9QeVBqdh3ETbS119RuPbg2QJF4Ph0g8j352kznIq47BnsX8JqNe", "https://www.researchgate.net/journal/Revista-de-la-Asociacion-Colombiana-de-Dermatologia-y-Cirugia-Dermatologica-1657-0448", "https://www.wikidata.org/wiki/Q96721629", "https://openaccessbutton.org/", "https://www.ncbi.nlm.nih.gov/myncbi/asistente%20editorial.revista.1/bibliography/public/", "https://pesquisa.bvsalud.org/gim/?lang=es&_charset_=UTF-8&index=&filter%5Bdb%5D%5B%5D=&q=Revista+de+la+Asociaci%C3%B3n+Colombiana+Dermatolog%C3%ADa+y+Cirug%C3%ADa+Dermatol%C3%B3gica", "https://pesquisa.bvsalud.org/portal/?lang=es&home_url=http%3A%2F%2Flilacs.bvsalud.org&home_text=Base+de+datos+LILACS%2C+informaci%C3%B3n+en+salud+da+Am%C3%A9rica+Latina+y+el+Caribe&filter%5Bdb%5D%5B%5D=LILACS&q=Revista+de+la+Asociaci%C3%B3n+Colombiana+de+Dermatolog%C3%ADa+y+Cirug%C3%ADa+Dermatol%C3%B3gica&submit=", "https://scholar.google.com/citations?hl=es&user=B5Osop4AAAAJ", "https://www.facebook.com/asocolderma", "https://twitter.com/asocolderma", "https://issuu.com/asocolderma_web", "/index.php/asocolderma/es", "/index.php/asocolderma/es", "https://revista.asocolderma.org.co/index.php/asocolderma/libraryFiles/downloadPublic/3", "https://revista.asocolderma.org.co/index.php/asocolderma/libraryFiles/downloadPublic/4", "https://revista.asocolderma.org.co/index.php/asocolderma/libraryFiles/downloadPublic/5", "https://revista.asocolderma.org.co/index.php/asocolderma/libraryFiles/downloadPublic/6", "https://revista.asocolderma.org.co/index.php/asocolderma/libraryFiles/downloadPublic/7", "https://revista.asocolderma.org.co/index.php/asocolderma/libraryFiles/downloadPublic/8", null, "https://asocolderma.org.co/", "https://revista.asocolderma.org.co/index.php/asocolderma/about/aboutThisPublishingSystem"]}